Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Financing Activities (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Cash from Financing Activities for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 160.74% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$5.1 million, a 76.37% decrease, with the full-year FY2024 number at -$131000.0, up 98.92% from a year prior.
  • Cash from Financing Activities was -$1.3 million for Q3 2025 at Harvard Bioscience, down from -$1.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $2.6 million in Q4 2021 to a low of -$4.1 million in Q4 2023.
  • A 5-year average of -$1.0 million and a median of -$1.2 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 3177.66% in 2023, then skyrocketed 176.51% in 2024.
  • Harvard Bioscience's Cash from Financing Activities stood at $2.6 million in 2021, then plummeted by 205.24% to -$2.7 million in 2022, then tumbled by 50.77% to -$4.1 million in 2023, then soared by 67.03% to -$1.4 million in 2024, then increased by 5.82% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Cash from Financing Activities are -$1.3 million (Q3 2025), -$1.3 million (Q2 2025), and -$1.2 million (Q1 2025).